Business Services Industry
Takeda Pharmaceutical, Wyeth Launches ENBREL Anti-rheumatic Agent
JCNN News Summaries - Japan Corporate News Network, Mar 31, 2005 by Aki Tsukioka
Takeda Pharmaceutical (TSE: 4502) and Wyeth jointly announced on March 29 that they will begin distributing ENBREL, an injection solution for the treatment of rheumatoid arthritis (RA), on March 30.
ENBREL, which is currently approved in over 70 countries worldwide, is the only fully human anti-TNF receptor used as monotherapy for RA patients.
The two companies will jointly promote the agent, and conduct a post-marketing surveillance study.
c 2005 Japan Corporate News Network. All rights reserved.
Provided by ProQuest Information and Learning Company. All rights Reserved.
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- Design a commission plan that drives sales - Sales Commissions
Most Popular Business Publications
Content provided in partnership with
Presented by the Premiere Rewards Gold Card from American Express